
Addendum

Bio VentureForum East 2007

Current as of Wednesday, June 13, 2007. Schedule subject to change.
Please check daily schedule posted in corridors.

Program Updates 2

Additional Profiles 5

Program Updates

Beyond Seed Funding: What a CEO Needs to Know About Creating Value to Attract Capital

Workshop
Tues., 3:30 PM, Viger C

MODERATOR: Alan F. Eisenberg, Executive Vice President for Emerging Companies and Business Development, Biotechnology Industry Organization

PANELISTS:

- **NEW** — Ben Perkins, Managing Director, Life Sciences Group, Pacific Growth Equities, LLC
- Dennis Purcell, Senior Managing Director, Aisling Capital LLC
- Paul K. Wotton, PhD, President & CEO, TOPIGEN Pharmaceuticals Inc.
- Alex Zisson, Partner, Thomas, Mc Nerney & Partners

Who's Who

Ben Perkins is a Managing Director in the Life Sciences group at Pacific Growth Equities, LLC. Ben has been actively involved in the Life Sciences sector for more than 10 years working on both the buy-side and the sell-side. Since joining Pacific Growth in 1999, Ben has advised clients in raising more than \$4 billion dollars through public and private equity transactions. In addition to fundraising, Ben has served as a strategic advisor to clients in the medical device, biotech, specialty pharmaceutical and diagnostics /tools sectors. Prior to Pacific Growth Equities, Ben focused on medical device, healthcare service and healthcare software/internet companies at Advest Group.

Rules of Engagement: Best Practices for Working with the FDA

Plenary
Wed., 8:15 AM, Salon de Bal

MODERATOR: Ramsey Baghdadi, Managing Editor, *The RPM Report*

PANELISTS:

- Wilson Bryan, MD, Senior Clinical Consultant, Biologics Consulting Group
- Thomas Q. Garvey, III, MD, President, Garvey Associates, Inc
- Ulrich Grau, President & CEO, Lux Biosciences
- **NEW** — Anna Pettersson, PhD, Senior Associate, Booz Allen Hamilton

Who's Who

Anna Pettersson, a Senior Associate at Booz Allen Hamilton's New York office, concentrates in the healthcare field with a focus on the pharmaceutical and biotechnology industries, where she specializes in R&D. Before joining the firm, Anna worked as a financial analyst and intellectual property consultant. She also has experience in academia and conducted research on the subjects of genetics and diabetes.

Schedule subject to change. Please check daily schedule posted in corridors.

Program Updates

Is the Traditional VC Model Broken?

Plenary

Wed., 2:30 PM, Salon de Bal

MODERATOR: Sara Jane Demy, Vice President, Business Development and Investor Relations, Biotechnology Industry Organization

PANELISTS:

- **NEW** — Scott R. Naisbitt, MD, PhD, Principal, RiverVest Venture Partners
- Barbara S. Schilberg, Managing Director and Chief Executive Officer, BioAdvance
- Steven Tregay, PhD, Managing Director, Novartis Option Fund
- Samuel Wu, MD, PhD, Principal, SV Life Sciences
- **CANCELLED** — Asish K. Xavier, PhD, Principal, Johnson & Johnson Development Corporation

Who's Who

Scott Naisbitt is a principal of RiverVest and former Kauffman Fellow. He has experience in medical device development and a strong background in molecular biology, clinical medicine, and neuroscience. Before joining RiverVest, he was an associate of Seedling Enterprises, a medical device fund and incubator, where he evaluated potential investments and co-invented an electrosurgical instrument successfully sold to a major medical device and pharmaceutical company. At RiverVest, Dr. Naisbitt focuses on both biopharmaceutical and medical device investments. He currently serves as a board observer at CGI Pharmaceuticals and Kereos, both Fund I portfolio companies.

Dr. Naisbitt has clinical and research experience at the Harvard-M.I.T. Division of Health Sciences and Technology, Massachusetts General Hospital, and Harvard Medical School. He has multiple research publications including the discovery of a physical bridge linking NMDA and metabotropic glutamate receptors, key mechanistic components of learning and memory.

Dr. Naisbitt has an MD and PhD from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, where he was awarded an N.I.H. Medical Scientist Training Program Scholarship. He also received a BS in physics and mathematics from the University of Utah.

Additional Profiles

Bio® VentureForum East 2007

Company profiles received after May 25, 2007 are included in this addendum.
They are not listed in the index in the conference handbook

Bio[®]
BIOTECHNOLOGY
INDUSTRY ORGANIZATION

NOTES

The information in this book was obtained from the participating companies. BIO does not guarantee that the information is complete or accurate, and does not warrant the information for a particular use or purpose.

A number of the participating companies may be clients of the conference sponsors or may be members of BIO.

Ash Access Technology, Inc.

Infectious Diseases, Renal, Vascular Access

Photo not provided.

Robert B. Truitt
President & CEO

3601 Sagamore Pkwy N
Suite B
Lafayette, IN 47904
USA

www.ashaccess.com
1 (608) 217-8593

Incorporated: 2003
Employees: 7
Ownership: Private

HIGHLIGHTS

Recent

More than 250 patients enrolled in the Zuragen Injection clinical trial as of June 2007 achieving the 50% to enrollment target

Ash Access Technology SBIR Grant application receives almost a perfect score (120) and the company is awarded \$2.7 million in a phase I/II fast track grant for the support of the Zuragen Injection clinical trial

DaVita clinical research partners with Ash Access Technology on the pivotal Zuragen Injection clinical trial. DaVita will provide Site Management services which include the identification of Principal Investigators, Coordinators and patients.

Upcoming

FDA approval of Ash Access Technology, Inc.'s Ash Advance Catheter; innovative function and design in hemodialysis vascular access

Announcement of a key strategic partnership with a reputable medical device company for the commercialization and distribution of the company's vascular access portfolio

Successful completion of the Zuragen Injection clinical program and final submission to FDA

CORPORATE MISSION

Commercialize Zuragen™ Injection, an innovative, first-to-market antimicrobial and antithrombotic therapy for the prevention of catheter-related bloodstream infections, a billion dollar plus unmet healthcare need.

PROPRIETARY TECHNOLOGY

Novel, non-antibiotic formulation shown to rapidly and effectively eliminate a broad spectrum of bacteria and penetrate and eradicate biofilm. This formulation also has antithrombotic properties to promote vascular access patency and reduce the need to use heparin.

INTELLECTUAL PROPERTY

Numerous patents and patent applications designed to protect the Zuragen core asset

CURRENT ALLIANCES

To be determined

PRODUCTS

Name	Phase	Indication	Milestone
Zuragen Injection	III	Prevention of catheter-related bloodstream infection	Target completion of enrollment Q3 2007
Ash Advance Hemodialysis Catheter	510(k) Submitted March 2007	Hemo Vascular Access	Waiting for final FDA response
Ash MaxFlow Peritoneal Dialysis Catheter	Testing and development	PD	Target 510(k) submission Q1 2008
Ash SureFlow Hemodialysis Catheter	Testing and development	Hemo Vascular Access	TBD
BaxCath Catheter Coating / Impregnation		Antimicrobial catheter coating	

FINANCING HISTORY

Investor Name (Ownership): **Chigwell Consulting** (8.45%) • **Stephen R. Ash, MD** (6.41%) • **Partisan Management** (5.95%) • **Bear Stearns Healthcare Value Fund** (4.86%) • **Robert B. Truitt** (4.81%)

SENIOR MANAGEMENT

Robert B. Truitt, President & CEO • **Stephen R. Ash, MD**, Director of R&D and Medical Director • **Carmine J. Durham**, VP Corporate Development and Commercial Strategy • **Roland K. Winger, P.E.**, VP Clinical and Product Development • **Alvaro F. Guillem, PhD**, VP Scientific and Quality Affairs • **Nels P. Bergmark**, Treasurer

BOARD OF DIRECTORS

Stephen R. Ash, MD, Director of R&D and Medical Director, Ash Access Technology • **Robert B. Truitt**, President and CEO, Ash Access Technology • **Joseph H. Broecker**, Chairman and Managing Director, Periculum Capital • **Lorelei D. Davis**, Partner, Frantz Medical Ventures • **Adel Korkor, MD**, Medical Director and CEO, Purity Dialysis Center • **Domenick Treschitta**, Principal, Ballard Medical Products • **Norman R. Weldon, PhD**, Managing Director, Partisan Management Group

SCIENTIFIC ADVISORY BOARD

Anatole (Tony) Besarab, MD, Professor of Medicine, Wayne State University, Henry Ford Health System • **Dennis Maki, MD**, Professor of Medicine, Section Chief, Dept. of Infectious Disease, University of Wisconsin • **Gerald Beathard, MD**, Associate Professor of Medicine, University of Texas and LSU School of Medicine • **Leonard Mermel, D.O.**, Professor of Medicine, Brown University, Div. of Infectious Disease



Donald F. Corcoran

President & CEO

7220 Frederick Banting Street
Montreal, QC H4S 2A1
Canada

www.methylgene.com
1 (514) 337-3333 x 224

Incorporated: 1997
Employees: 113
Ownership: Public
TSX: MYG

HIGHLIGHTS

Recent

Announced clinical data for MGCD0103 at ASCO.
40% response rate in Phase II relapsed and refractory Hodgkin's lymphoma. 30% response rate in Phase I/II MDS/AML trial
Closed a CDN \$20.1 million public equity financing on March 2, 2007
MGCD265 selected as MethylGene's multi-targeted kinase (c-MET) clinical candidate for oncology

Upcoming

Anticipate an IND filing for our multi-targeted (c-Met) kinase inhibitor, MGCD265
Commence additional MGCD0103 (HDAC inhibitor for oncology) clinical trials
Continue to advance preclinical HDAC non-oncology programs

CORPORATE MISSION

MethylGene Inc. (TSX:MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company focuses on some of the most promising areas of oncology such as histone deacetylase (HDAC) and kinase inhibitors. The Company's lead product is MGCD0103, an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza® and Gemzar®. MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical HDAC programs in non-oncology indications such as fungal infections (clinical candidate MGCD290 in combination with azoles to overcome resistance), and Huntington's disease. The company also has a beta-lactamase program to overcome antibiotic resistance. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at www.methylgene.com.

PROPRIETARY TECHNOLOGY

MethylGene's drug discovery approach is to identify and validate specific enzyme isoforms involved in disease. Rational drug design and medicinal chemistry are employed to design, synthesize and optimize compounds for clinical development. MethylGene seeks out high-quality enzyme targets for cancer and non-oncology indications, potentially applicable to multiple indications and commercially attractive.

INTELLECTUAL PROPERTY

We have protected our product pipeline with multiple layers of intellectual property. We file patents covering composition of matter, use and biological targets whenever possible.

CURRENT ALLIANCES

Pharmion Corporation (NASDAQ : PHRM)

- Oncology collaboration for MGCD0103 and 2nd generation small molecule HDAC inhibitors for North America, Europe, Middle East and other markets
- Deal worth up to US \$272 million, including upfront payment of US \$25 million
- Milestone payments totaling up to US \$245 million
- 60% funding of preclinical and clinical development in North America
- Royalties to 20% or option to co-promote and receive 50% of profit

Taiho Pharmaceutical

- Oncology collaboration for MGCD0103 and 2nd generation small molecule HDAC inhibitors for Japan, China, Taiwan and Korea
- Deal value up to US \$30 million, including upfront payment of US \$4 million
- Milestone payments totaling up to US \$16 million for first product, additional milestone for subsequent product
- US \$9 million funding for North American preclinical and clinical development
- Taiho responsible for clinical development in their territory
- Royalties from Taiho territory
- MethylGene retains 100% commercialization rights in the rest of the world

Merck

- Worldwide exclusive license for small molecule inhibitor program against bacterial beta-lactamases for antibiotic resistance
- Merck responsible for preclinical and clinical development and worldwide commercialization marketing of lead molecules
- US \$33.75 million royalty and milestone payments
- Merck has selected an optimized lead which is currently undergoing preclinical studies

EnVivo Pharmaceuticals

- Agreement to exploit our HDAC inhibitors in neurodegenerative diseases such as Huntington's Parkinson's and Alzheimer's

MethylGene received US \$1.1 million in contract research payment and license fees

PRODUCTS

Name	Phase	Indication	Milestone
MGCD0103 (HDAC inhibitor)	Two Phase I/II trials in combination with Vidaza and Gemzar; Three Phase II monotherapy trials	Cancer	Commence additional trials
MGCD265 (Multi-targeted kinase inhibitor)	preclinical	Cancer	File IND
MGCD290	Preclinical	Fungal infections	Clinical candidate recently selected
Next generation HDAC inhibitors	Preclinical	Cancer	
HDAC inhibitors (non-oncology)	Preclinical	Neurodegenerative diseases,	Advance program
Beta-lactamase inhibitor	Preclinical	Antibiotic Resistance	

SENIOR MANAGEMENT

Donald F. Corcoran, President & CEO • **Jeffrey M. Besterman**, Executive Vice-President, R&D and CSO • **Klaus Kepper**, Vice-President, Finance & CFO • **Robert E. Martell**, Vice-President and Chief Medical Officer

BOARD OF DIRECTORS

Raymond C. Egan, Former Executive & Senior VP, Bristol Myers Squibb • **Donald F. Corcoran**, President & CEO, MethylGene Inc. • **David J. Drutz, MD**, General Partner, Pacific Rim Ventures • **Martin Godbout, PhD**, President & CEO, Genome Canada • **Gaetan Gravel**, Portfolio Manager, Fonds de Solidarité des Travailleurs du Qu • **Louis Lacasse**, President, Genechem Management Inc. • **Colin Mallet**, Former President, Sandoz Canada • **Jay Moorin**, Partner, ProQuest Investments

<i>Photo not provided.</i>	J. Kelly Ganjei <i>President & CEO</i>		
	803 Reserve Champion Dr., #302 Rockville, MD 20850 USA	www.remegenix.com 1 (202) 679-7456	<i>Incorporated:</i> 2006 <i>Employees:</i> 3 <i>Ownership:</i> Private

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
Executed exclusive licenses to 2 product portfolio's from Georgetown University and Albert Einstein College of Medicine	Completion of pre-clinical work for IND submission
Completed our Pre-IND meeting with the FDA	IND submission
Venture funding from the State of Maryland and Montgomery County	Phase I clinical trial

CORPORATE MISSION
RemeGenix, Inc (RGX) is a start-up company located in Maryland specializing in the development and commercialization of therapies for neurodegenerative diseases. Specifically, RGX will focus on the commercialization of technologies with well-validated models for the treatment of unmet neurodegenerative diseases such as Alzheimer's and Traumatic Brain injury. Unlike most other competitive products in development, RGX's lead technology does not interfere with alternative important biological pathways, and is focused on the cause of the disease versus treating the symptoms.
PROPRIETARY TECHNOLOGY
The most promising product candidates in RGX' portfolio are focused on treating the causes (versus the symptoms) of neurodegenerative conditions. Our two product candidates are directed at addressing the multiple pathologies of AD with the potential for expansion into other neurodegenerative diseases such as Parkinson's disease (PD), Schizophrenia, bipolar disorder (BP), and general cognitive disorders. Our most clinically developed product is the result of years of scientific research into the therapeutic potential of the Thyrotropin releasing hormone (TRH) for use in traumatic injuries and general cognitive disorders.
INTELLECTUAL PROPERTY
We currently have one granted patent, and several international pending applications for one product candidate and two pending applications and 1 PCT on our Alzheimer's technology.

CURRENT ALLIANCES
We are in the early stages of developing corporate alliances. While we have several in progress we have not issued press releases on these yet.

PRODUCTS			
<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
RGx-100	Pre-Clinical	Alzheimer's Disease, Dementia	Lead Candidate Selection and Optimization
RGx-400	Pre-Clinical	Traumatic Brain Injury	Pre-IND Meeting completed, 6mos to IND

FINANCING HISTORY
<i>Investor Name (Ownership):</i> Founders (60%)

SENIOR MANAGEMENT
J. Kelly Ganjei , President & CEO

BOARD OF DIRECTORS
Luciano D'Adamo, MD, PhD , Chairman, Albert Einstein College of Medicine • J. Kelly Ganjei , President, Director, RemeGenix • Salvatore Oliviero, PhD , Director, University di Siena, Italy

Traxion Therapeutics Inc.

CNS, Drug Development, Pain



Kerrie Brady
President & CEO

1303 South Potomac Street
Baltimore, MD 21224
USA

www.traxiontx.com
1 (301) 325-3718

Incorporated: 2006
Employees: 36
Ownership: Private

HIGHLIGHTS

Recent

Seed financing from Challenge Fund
Commercial rights to TXT-0100 from Japanese pharmaceutical company A
Commercial rights to TXT-0200 and TX-0400 from Japanese pharmaceutical company B

Upcoming

Series A financing
TXT-0100 Phase I commencement
TXT-0200 Phase I commencement

CORPORATE MISSION

Traxion Therapeutics is developing novel, targeted oral drugs for the treatment of neuropathic pain. Traxion has a diversified portfolio which includes two compounds in late preclinical stage being developed to treat diabetic, HIV and post-herpetic neuropathic pain.

PROPRIETARY TECHNOLOGY

TXT-0100 – preclinical, novel, orally active drug which acts at the peripheral sigma 1 receptor. Importantly TXT-0100 does not enter the CNS and therefore is able to provide analgesia without CNS side effects. Analgesic activity of TXT-0100 has been demonstrated in several animal models of neuropathic pain, with particularly impressive results in diabetic neuropathy compared to pregabalin or duloxetine. Preliminary pharmacokinetic, safety and toxicology studies have been done and patents filed. TXT-0100 is sourced from a Japanese pharmaceutical company

TXT-0200 – preclinical, novel, orally active drug which blocks the Cav2.2 (N-type calcium channel) receptor. TXT-0200 has shown promising analgesic activity in several animal models of neuropathic pain. Compared to gabapentin, TXT-0200 provides more potent analgesic activity with few behavioral side effects. Preliminary pharmacokinetic, safety and toxicology studies have been done and patents filed. TXT-0200 is sourced from a Japanese pharmaceutical company,

TXT-0400 - preclinical, novel, orally active drug which blocks the TRPV1 receptor. Has shown potent activity in animal models of chronic and inflammatory pain. Preliminary pharmacokinetic, safety and toxicology studies have been done and patents filed. TXT-0400 is sourced from a Japanese pharmaceutical company.

INTELLECTUAL PROPERTY

TXT-0100: portfolio covering composition of matter and use patents.
TXT-0200: portfolio covering composition of matter and use patents
TXT-0400: portfolio covering target, composition of matter and use patents

CURRENT ALLIANCES

Japanese pharmaceutical company A,
Japanese pharmaceutical company B

PRODUCTS

<i>Name</i>	<i>Phase</i>	<i>Indication</i>	<i>Milestone</i>
TXT-0100	diabetic neuropathic pain	late preclinical	Phase I clinical trial 2008
TXT-0200	HIV & post-herpetic neuropathic pain	late preclinical	Phase I clinical trial 2008
TXT-0400	chronic pain	preclinical	Phase I clinical trial 2009

FINANCING HISTORY

Investor Name (Ownership): **Founders & Management (98%) • University of Maryland (2%)**

SENIOR MANAGEMENT

Kerrie Brady, President & CEO

BOARD OF DIRECTORS

Kerrie Brady, President & CEO, Traxion Therapeutics Inc • **James Foley, PhD**, CEO, SMART Biosciences • **Blanche Johnson, PhD**, consultant • **Arthur Michaelis, PhD**, consultant

SCIENTIFIC ADVISORY BOARD

Anthony Altar, PhD, Director, The Biomarkers Consortium, Foundation for NIH • **Valentin Gribkoff, PhD**, Chief Scientific Officer, Knopp Neurosciences Inc., Yale Medical School • **Roger Johns, MD**, Professor, Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine • **Dr. Gavril Pasternak**, Chair of Neurology, Memorial Sloan-Kettering Cancer Center • **Dr. James Campbell**, Professor of Neurosurgery, Johns Hopkins University School of Medicine